|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
|
25792709 |
2016 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
|
26715116 |
2015 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human hepatocellular cancers (HCC) lack RAS mutations but are frequently mutated in CTNNB1, the human Catnb ortholog.
|
15965925 |
2005 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
|
19101982 |
2009 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The liver cancer-specific signature 16, associated with alcohol, displays a unique feature of transcription-coupled damage and is the main source of CTNNB1 mutations.
|
29101368 |
2017 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study confirms that beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer.
|
17962810 |
2008 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that most colorectal and liver cancers with mutations in components of the β-catenin degradation complex do not strongly rely on extracellular Wnt ligand exposure to support optimal growth.
|
27851986 |
2016 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in <i>CTNNB1</i>, the gene encoding β-catenin, are common in colon and liver cancers, the most frequent mutation affecting Ser-45 in β-catenin.
|
31690625 |
2019 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.
|
17030191 |
2006 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the current investigation was to define the prevalence of genetic alterations in p16 and beta-catenin in NNK-induced rat liver cancer to determine if the molecular mechanisms seen in human tumors are the same in this animal model.
|
11238187 |
2001 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the EBP50/beta-catenin complex promotes Wnt signaling, and over-expression of EBP50 may work cooperatively with beta-catenin in the development of liver cancer.
|
12830000 |
2003 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer.
|
28807594 |
2017 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We frequently detected the active form of beta-catenin and accumulation of nuclear beta-catenin in liver cancer cell lines.
|
18592156 |
2008 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
CTD_human |
Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen.
|
21047994 |
2011 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
|
17283120 |
2007 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor suppressor function of ezrin-radixin-moesin-binding phosphoprotein-50 through β-catenin/E-cadherin pathway in human hepatocellular cancer.
|
23483729 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that BCA exerts its cytotoxic effects by promoting phosphorylation/ubiquitin-dependent degradation of β-catenin and may potentially serve as a chemopreventive agent for colonrectal and liver cancers.
|
31163223 |
2019 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.
|
23555187 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of β-Catenin.
|
31322782 |
2019 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Let7b modulates the Wnt/β-catenin pathway in liver cancer cells via downregulated Frizzled4.
|
28671046 |
2017 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, we identified a number of candidate Wnt/beta-catenin target genes that can be useful for studying the role of altered Wnt signaling in liver cancer development, and showed that some of them might be direct targets of Wnt signaling in hepatoma cells.
|
17157329 |
2007 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
CTD_human |
Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis.
|
10467420 |
1999 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/beta-catenin activation is observed in normal liver development, regeneration, and liver cancer.
|
16012954 |
2005 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, we conclude that suppression of both Sirt1 and Wnt/βCatenin might be effective in treating liver cancer.
|
28583374 |
2017 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
|
30359743 |
2019 |